| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
14,820,000 |
| Market
Cap: |
10.37(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6218 - $0.83 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Magenta Therapeutics is a clinical-stage biotechnology company. Co.'s primary targeted conditioning program, MGTA-117, has entered clinical development, and its second program, a CD45-antibody drug conjugate, is advancing in preclinical development. In addition, Co. is developing a product candidate, MGTA-145, to improve the process by which stem cells are stimulated out of the bone marrow and into the bloodstream so they are available for collection for future reinfusion, known as mobilization, which is required for transplants and gene therapy applications. MGTA-145 is a clinical stage program intended to enable mobilization and collection of functional stem cells for transplant.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
82,924 |
82,924 |
| Total Buy Value |
$0 |
$0 |
$1,056,732 |
$1,056,732 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
6 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
3,700,000 |
| Total Sell Value |
$0 |
$0 |
$0 |
$3,056,000 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gardner Jason |
See Remarks |
• • – |
2019-06-20 |
4 |
AS |
$15.10 |
$25,202 |
D/D |
(1,669) |
361,543 |
|
- |
|
| Cooke Michael P. |
Chief Scientific Officer |
• – – |
2019-06-17 |
4 |
AS |
$13.90 |
$104,267 |
D/D |
(7,500) |
285,523 |
|
- |
|
| Booth Bruce |
Director |
– • – |
2019-03-20 |
4 |
S |
$17.86 |
$254,416 |
I/I |
(14,245) |
0 |
|
- |
|
| Booth Bruce |
Director |
– • – |
2019-03-20 |
4 |
A |
$0.00 |
$0 |
I/I |
14,245 |
14,245 |
|
- |
|
| Booth Bruce |
Director |
– • – |
2019-03-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(726,500) |
4,117,125 |
|
- |
|
| Atlas Venture Associates X, Llc |
10% Owner |
– – • |
2019-03-20 |
4 |
S |
$17.86 |
$254,416 |
I/I |
(14,245) |
0 |
|
- |
|
| Atlas Venture Associates X, Llc |
10% Owner |
– – • |
2019-03-20 |
4 |
A |
$0.00 |
$0 |
I/I |
14,245 |
14,245 |
|
- |
|
| Atlas Venture Associates X, Llc |
10% Owner |
– – • |
2019-03-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(726,500) |
4,117,125 |
|
- |
|
| Trv Gp Iv, Llc |
10% Owner |
– – • |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
7,911,455 |
8,008,204 |
|
- |
|
| Borisy Alexis |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
0 |
0 |
|
- |
|
| Zdraveski Zoran |
See Remarks |
• – – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,643 |
140,092 |
|
- |
|
| Isacson Christina K. |
Chief Business Officer |
• – – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,912 |
103,531 |
|
- |
|
| Bonney Michael W |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
21,847 |
215,346 |
|
- |
|
| Drifka Amy L |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
593,611 |
593,611 |
|
- |
|
| Cooke Michael P. |
Chief Scientific Officer |
• – – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,370 |
293,023 |
|
- |
|
| Scadden David |
Director |
– • – |
2018-06-25 |
4 |
B |
$15.00 |
$99,000 |
D/D |
6,600 |
228,175 |
2.39 |
- |
|
| Scadden David |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
28,076 |
221,575 |
|
- |
|
| Alphabet Inc. |
10% Owner |
– – • |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
3,339,137 |
3,339,137 |
|
- |
|
| Atlas Venture Associates X, Llc |
10% Owner |
– – • |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,746,876 |
4,843,625 |
|
- |
|
| Booth Bruce |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
4,746,876 |
4,843,625 |
|
- |
|
| Byers Blake |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
3,339,137 |
3,339,137 |
|
- |
|
| Daniel Thomas O |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
24,527 |
101,926 |
|
- |
|
| Davis John C. Jr |
Chief Medical Officer |
• – – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,304 |
8,304 |
|
- |
|
| Albers Jeffrey W. |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,152 |
4,152 |
|
- |
|
| Gardner Jason |
See Remarks |
• • – |
2018-06-25 |
4 |
B |
$15.00 |
$6,000 |
D/D |
400 |
363,212 |
2.81 |
- |
|
101 Records found
|
|
Page 4 of 5 |
|
|
